The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02312206|
Recruitment Status : Terminated (The NEOD001 program was terminated due to lack of clinical benefit)
First Posted : December 9, 2014
Last Update Posted : June 8, 2018
|Condition or disease||Intervention/treatment||Phase|
|Primary Systemic (AL) Amyloidosis||Drug: NEOD001 Other: Placebo||Phase 3|
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Approximately 236 subjects will be enrolled in ~60 centers, with approximately 118 subjects per arm.
This is an event driven trial, therefore subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or cardiac hospitalizations) have been reached. All subjects who discontinue will be followed until the last event is adjudicated. The estimated overall study duration is approximately 42 months, including the enrollment and treatment periods
Study drug will be administered once every 28 days as a 60-120 minute IV infusion.
First-line chemotherapy must be a proteasome inhibitor-containing regimen, with the proteasome inhibitor administered weekly. The number of cycles of first-line chemotherapy that are administered are at the discretion of the Investigator, and subsequent chemotherapy regimens may be prescribed as per standard of care at the Investigator's discretion.
An independent Data Monitoring Committee (DMC) will review data on a regular basis.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||260 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis|
|Study Start Date :||February 2015|
|Actual Primary Completion Date :||May 2018|
|Actual Study Completion Date :||May 2018|
24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
Placebo Comparator: Placebo
Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
- Time to composite of all-cause mortality or cardiac hospitalization [ Time Frame: From date of randomization until the date of death or cardiac hospitalization, whichever came first, assessed for up to approximately 42 months ]
- NT-proBNP best response [ Time Frame: Baseline to Month 9 ]
- Time to cardiac mortality or cardiac hospitalization [ Time Frame: Baseline to Month 9 ]
- Change in the 6 Minute Walk Test [ Time Frame: Baseline to Month 9 ]
- Change in the Short Form-36 Questionnaire [ Time Frame: Baseline to Month 9 ]
- Change in the Kansas City Cardiomyopathy Questionnaire [ Time Frame: Baseline to Month 9 ]
- Renal best response [ Time Frame: Baseline to Month 9 ]As assessed using Palladini et al, 2014 criteria
- Hepatic best response assessed using Comenzo et al, 2012 criteria [ Time Frame: Baseline to Month 9 ]As assessed using Comenzo et al, 2012 criteria
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02312206
Show 79 Study Locations